Genomic sequencing Investigation of 733 HER2-amplified primary and metastatic breast tumours revealed sizeable enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours taken care of with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. A critical thought https://www.directivepublications.org/journal-of-clinical-breast-cancer/